1. Home
  2. INLX vs IGC Comparison

INLX vs IGC Comparison

Compare INLX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

HOLD

Current Price

$5.45

Market Cap

26.4M

Sector

Technology

ML Signal

HOLD

Logo IGC Pharma Inc.

IGC

IGC Pharma Inc.

HOLD

Current Price

$0.26

Market Cap

28.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
IGC
Founded
1996
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.4M
28.4M
IPO Year
2013
2005

Fundamental Metrics

Financial Performance
Metric
INLX
IGC
Price
$5.45
$0.26
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.25
AVG Volume (30 Days)
6.7K
482.1K
Earning Date
05-14-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.09
EPS
N/A
N/A
Revenue
$11,336.00
$1,271,000.00
Revenue This Year
$16.86
N/A
Revenue Next Year
N/A
$13.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$0.24
52 Week High
$13.66
$0.50

Technical Indicators

Market Signals
Indicator
INLX
IGC
Relative Strength Index (RSI) 41.90 N/A
Support Level $5.45 N/A
Resistance Level $7.87 N/A
Average True Range (ATR) 0.21 0.00
MACD -0.01 0.00
Stochastic Oscillator 6.96 0.00

Price Performance

Historical Comparison
INLX
IGC

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Share on Social Networks: